The acquisition of Anthos Therapeutics could be worth up to $3.1 billion and returns to Novartis a blood thinner it licensed ...
Exane analyst Victor Floch upgraded Genmab (NASDAQ:GMAB) A/S shares from Underperform to Neutral, adjusting the price target to DKK1,500 from DKK2,000. The revision comes as Genmab, a Danish ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback